原发性胆汁性肝硬化的发病机制及影响预后的危险因素研究进展

刘红虹; 福军亮; 付宝云; 张政; 徐若男; 罗生强; 施明; 李永纲; 王福生

原发性胆汁性肝硬化的发病机制及影响预后的危险因素研究进展

1. 军医进修学院
2. 解放军第302医院中西医结合肝病诊疗与研究中心

基金项目:

国家“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项项目(2009ZX10004-309)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 3338
- HTML全文浏览量: 26
- PDF下载量: 729
- 被引次数: 0
出版历程
- 出版日期: 2012-02-20

The pathogenesis and risk factors related to prognosis of primary biliary cirrhosis

Research funding:

摘要

摘要: 原发性胆汁性肝硬化(PBC)是一种原因不明的,自身免疫介导的,以肝内中、小胆管胆汁淤积为特征的肝病。本文就目前国内外已报道的PBC的发病机制及影响其预后的相关危险因素进行综述。
- 肝硬化,胆汁性 /
- 发病机制 /
- 预后 /
- 危险因素
Abstract: Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by autoimmune-mediated destruction of small-and medium-sized intrahepatic bile ducts.Although many studies reported that PBC results from a combination of multiple genetic factors and superimposed environmental trigger, the precise mechanisms under the disease progression are still unknown.We summarized the pathogenesis and risk factors related to prognosis of PBC in this review.
- live cirrhosis /
- biliary /
- pathogenesis /
- prognosis

HTML全文

参考文献(26)

[1]Metcalf JV, Bhopal RS, Gray J, et al.Incidence and preva-lence of primary biliary cirrhosis in the city of Newcastle up-on Tyne, England[J].Int J Epidemiol, 1997, 26 (4) :830-836.

[2]Kim WR, Lindor KD, Locke GR III, et al.Epidemiology andnatural history of primary biliary cirrhosis in a US[J].Gastro-enterology, 2000, 119 (6) :1631-1636.

[3]Gershwin ME, Selmi C, Worman HJ, et al.Risk factors andcomorbidities in primary biliary cirrhosis:a controlled inter-view-based study of 1032 patients[J].Hepatology, 2005, 42 (5) :1194-12.

[4]Ala A, Stanca CM, Bu-Ghanim M, et al.Increased preva-lence of primary biliary cirrhosis near super fund toxic wastesites[J].Hepatology, 2006, 43 (3) :525-531.

[5]Zein CO, Beatty K, Post AB, et al.Smoking and increased se-verity of hepatic fibrosis in primary biliary cirrhosis:A cross vali-dated retrospective assessment[J].Hepatology, 2006, 44 (6) :1564-1571.

[6]Leung PS, Park O, Tsuneyama K, et al.Induction of primarybiliary cirrhosis inguinea pigs following chemical xenobioticimmunization[J].J Immunol, 2007, 179 (4) :2651-2657.

[7]Hirschfield GM, Liu X, Xu C, et al.Primary biliary cirrhosisassociated with HLA, IL12A, and IL12RB2 variants[J].NEngl J Med, 2009, 360 (24) :2544-2555.

[8]Nakamura M, Yasunami M, Kondo H, et al.Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary bili-ary cirrhosis (PBC) :he HLA-DRB1 polymorphism deter-mines the relative risk of antinuclear antibodies for diseaseprogression in PBC[J].Hepatol Res, 2010, 40 (5) :494-504.

[9]陈燕, 周晔, 邓安梅, 等.中国东部汉族人群原发性胆汁性肝硬化与HLA2DRB1相关性分析[J].中国免疫学杂志, 2006, (22) 12:1143-1145.

[10]Muratori L, Granito A, Muratori P, et al.Antimitochondrialantibodies and other antibodies in primary biliary cirrhosis:di-agnostic and prognosticvalue[J].Clin Liver Dis, 2008, 12 (2) :261-276.

[11]Cavazzana I, Angela C, Paolo A, et al.Anti-RNA polymera-seIII antibodies:a marker of systemic sclerosis with rapid on-set and skin thickening progression[J].Autoimmun Rev, 2009, 8 (7) :580-584.

[12]Itoh S, Ichida T, Yoshida T, et al.Autoantibodies against a210kD aglycoprotein of the nuclearpore complex as a prog-nostic marker in patients with primary biliary cirrhosis[J].JGastroenterol Hepatol, 1998, 13 (3) :257-265.

[13]Muratori P, Muratori L, Ferrari R, et al.Characterization andclinical impact of antinuclear antibodies in primary biliary cir-rhosis[J].Am J Gastroenterol, 2003, 9 (2) 8:431-437.

[14]Miyachi K, Hankins RW, Matsushima H, et al.Profile andclinical significance of anti-nuclear envelope antibodiesfound in patients with primary biliary cirrhosis:a multicenterstudy[J].J Autoimmun, 2003, 20 (3) :247-254.

[15]VandeWater J, Turchany J, Leung PS, et al.Molecular mimicryin primary biliary cirrhosis.Evidence for biliary epithelial expres-sion of a moleculecross-reactive with pyruvate dehydrogenasecomplex-E2[J].J Clin Invest, 1993, 91 (6) :2653-2664.

[16]Guldner HH, Szostecki C, Gr tzinger T, et al.IFN enhanceexpression of Sp100, an autoantigen in primary biliary cirrho-sis[J].J Immunol, 1992, 149 (12) :4067-4073.

[17]Czaja AJ.Autoantibodies as prognostic markers in autoimmuneliver disease[J].Dig Dis Sci, 2010, 55 (8) :2144-2161.

[18]Nakamura M, Kondo H, Mori T, et al.Anti-gp210and anti-centromere antibodies are different risk factors for the pro-gression of primary biliary cirrhosis[J].Hepatology, 2007, 45 (1) :118-127.

[19]Poupon R, Chazouilleres O, Balkau B, et al.Clinical and bio-chemical expression of the histopathological lesions of prima-ry biliary cirrhosis[J].J Hepatol, 1999, 30 (3) :408-412.

[20]Degott C, Zafrani ES, Callard P, et al.Histopathological studyof primary biliary cirrhosis and the effect of ursodeoxycholic acidtreatment on histology progression[J].Hepatology, 1999, 29 (4) :1007-1012.

[21]Wesierska-Gadek J, Penner E, Battezzati PM, et al.Corre-lation of initial autoantibody profile and clinical outcome in pri-mary biliary cirrhosis[J].Hepatology, 2006, 43 (5) :1135-1144.

[22]Nakamura M, Takii Y, Ito M, et al.Increased expression ofnuclear envelope gp210 antigen in small bile ducts in primarybiliary cirrhosis[J].J Autoimmun, 2006, 26 (2) :138-145.

[23]Clouston AD, Powell EE, Walsh MJ, et al.Fibrosis corre-lates with aductular reaction in hepatitis C:roles of impairedreplication, progenitor cells and steatosis[J].Hepatology, 2005, 41 (4) :809-818.

[24]Lazaridis KN, Strazzabosco M, Larusso NF.The cholangiop-athies:isorders of biliary epithelia[J].Gastroenterology, 2004, 127 (5) :1565-1577.

[25]Gressner AM, Weiskirchen R.Modern pathogenetic conceptsof liver fibrosis suggest stellate cells and TGF-beta as majorplayers and therapeutic targets[J].J Cell Mol Med, 2006, 10 (1) :76-99.

[26]宫颜英, 王斯文, 房淑华, 等.晚期原发性胆汁性肝硬化患者外周血调节性T细胞表达分析[J].细胞与分子免疫杂志, 2011, 27 (3) :307-309.

施引文献

资源附件(0)

访问统计